Clinical trials: Thyroid Neoplasms
Cancer, Renal Cell Carcinoma (RCC)
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
The primary objective of this long-term extension study is to allow continued access to study treatment for eligible participants who are deriving clinical benefit in an Exelixis-sponsored study who do not have access to…
- Conditions
- Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET), Extra-Pancreatic NET (epNET)
- Trial name
- NCT07620574
- Testing
- Cabozantinib, Zanzalintinib, Atezolizumab
- Where
- 4 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- Exelixis
Thyroid Cancer
Selective Neck Dissection Versus Modified Neck Dissection in PTC
This study is a phase III, randomized controlled, open label non inferiority study. Patients who meet the inclusion criteria are randomly assigned 1:1 to either the experimental group (selective neck dissection) or the control…
- Trial name
- NCT06554652
- Testing
- Lymph node tracer navigated selective neck dissection, Modified neck dissection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Head and Neck Cancer
Radioimmunotherapy With or Without Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Thyroid Cancer
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004048
- Testing
- filgrastim, doxorubicin hydrochloride, autologous bone marrow transplantation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Thyroid Cancer
Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments.
- Trial name
- THY-CANC (NCT05752604)
- Where
- Italy
- Volunteers
- 3,000 people
- Sponsor
- Istituto Auxologico Italiano
Papillary Thyroid Cancer, Pediatric Cancer
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
Papillary thyroid cancer (PTC) is a common type of differentiated thyroid cancer (DTC) in children and represents the second most common cancer in adolescent females.
- Conditions
- Papillary Thyroid Cancer, Pediatric Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT05024929
- Testing
- Whole body scan
- Where
- 9 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- Children's Hospital of Philadelphia
Solid Tumors, CNS Tumors
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain…
- Trial name
- STARTRK-NG (NCT02650401)
- Testing
- Entrectinib
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 69 people
- Sponsor
- Hoffmann-La Roche
Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer
Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer
This phase II trial studies how well sorafenib tosylate works in treating younger patients with relapsed or refractory rhabdomyosarcoma, Wilms tumor, liver cancer, or thyroid cancer.
- Conditions
- Childhood Hepatocellular Carcinoma, Papillary Thyroid Cancer, Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Liver Cancer
- Trial name
- NCT01502410
- Testing
- sorafenib tosylate, pharmacological study, laboratory biomarker analysis
- Where
- 92 sites in United States, Australia and 1 more
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Thymic Epithelial Tumor, Teratoma
Establishing Prospective Mediastinal Tumor Database of PUMCH
This study aims to prospectively document the population characteristics, imaging findings, pathological features, prognostic factors, etc., of patients with mediastinal tumors.
- Conditions
- Thymic Epithelial Tumor, Teratoma, Thymic Cyst, Retrosternal Goitre
- Trial name
- MTDPUMCH (NCT06421805)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Peking Union Medical College Hospital
Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN2A or MEN2B) or familial…
- Trial name
- NCT01424878
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- National Cancer Institute (NCI)
Papillary Thyroid Cancer
The Role of Central Neck Dissection in Stage N0 Papillary Thyroid Carcinoma
The benefits of prophylactic central neck dissection (pCND) remain controversial in clinically node-negative (cN0) papillary thyroid carcinoma (PTC).
- Trial name
- pCND (NCT04076514)
- Testing
- central neck dissection
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Exploring the Prognostic Value of Tumor Deposits PTC Patients
Prognostic Value of Tumor Deposits for Patients With Papillary Thyroid Carcinoma
Tumor deposits (TD), nodules in the peritumoral adipose tissue with no architectural residue of lymph node, which is a definition often being confusing to the extranodal extension (ENE), have been described in several…
- Trial name
- NCT06051838
- Testing
- surgery
- Where
- China
- Volunteers
- 541 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Thyroid Cancer, Mediastinal Diseases
Lateral Approach for Mediastinal Lymph Node Dissection in Thyroid Cancer
Despite the numerous surgical approaches available for superior mediastinal lymph node dissection in thyroid cancer, many of these methods still have significant limitations.
- Conditions
- Thyroid Cancer, Mediastinal Diseases, Lymph Node Metastasis
- Trial name
- NCT06793579
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Chongqing General Hospital
Pleuropulmonary Blastoma, Cystic Nephroma
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome
Pleuropulmonary Blastoma (PPB) is a rare lung tumor which develops in childhood. The underlying genetic factors which contribute to the development and progression of PPB are not defined.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Sertoli-Leydig Cell Tumor of Ovary, Medulloepithelioma
- Trial name
- PPB (NCT00565903)
- Where
- United States
- Volunteers
- 1,247 people, healthy volunteers welcome
- Sponsor
- Ashley Hill
Pleuropulmonary Blastoma, Cystic Nephroma
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Background: Pleuropulmonary blastoma (PPB) is a rare fast-growing lung tumor that is associated with other, rare tumor types. Most cases of PPB appear in children younger than 6 years of age.
- Conditions
- Pleuropulmonary Blastoma, Cystic Nephroma, Ovarian Sertoli-Leydig Cell Tumors, Ocular Medulloepithelioma
- Trial name
- NCT01247597
- Where
- 2 sites in United States
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Huerthle Cell Carcinoma
Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma
The goal of this retrospective study is to evaluate in patients with HCC and FTC who underwent lobectomy. The main questions it aims to answer are: The necessity of completion thyroidectomy based on the clinicopathological…
- Trial name
- HCC and FTC (NCT05968196)
- Volunteers
- 221 people
- Sponsor
- The Catholic University of Korea
Thyroid Cancer
Selpercatinib and Body Composition
investigation of body composition
- Trial name
- EECRTKI (NCT07543887)
- Testing
- observation in patient under treatment, Selpercatinib
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Pisa
Thyroid Cancer
Lateral Neck Lymph Node Mapping in Thyroid Cancer
This study includes papillary thyroid cancer patients who have unpalpable lateral neck lymph nodes but suspicious on ultrasound and/or CT. Carbon nanoparticles is used as the tracer for lateral neck lymph node mapping.
- Trial name
- NCT04312087
- Testing
- Lateral neck sentinel lymph node biopsy, Modified lateral neck lymph node dissection, Super selective lateral neck lymph node dissection
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Incidence of Thyroid Cancer in Long Standing MNG
Risk of Malignancy in Endemic Long Standing Nodular Goitres: a Prospective Cohort Study
To determine the incidence of thyroid cancer in patients with long standing goitres presenting for surgery.
- Trial name
- NCT06405919
- Testing
- Histopathology
- Where
- Sudan
- Volunteers
- 160 people
- Sponsor
- University of Khartoum
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor
Expanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor.
- Trial name
- NCT05225259
- Testing
- LOXO-260
- Sponsor
- Eli Lilly and Company